nView Medical

nView Medical is a commercial-stage medical device company that has developed an integrated 3D imaging and surgical navigation platform, the nView s1™. The system combines low-dose 3D imaging, real-time instrument tracking ('True-Map Navigation™'), and AI to provide intraoperative planning and guidance, primarily for spinal and orthopedic surgeries. With FDA 510(k) clearance secured in 2021, the company has begun commercialization, marked key partnerships, and reported over 500 surgeries performed as of early 2025. The leadership team boasts extensive experience from GE Healthcare and other major medtech firms, driving the company's mission to improve surgical outcomes.

The nView s1™ is an integrated 3D imaging and surgical guidance platform. It combines very low-dose, instant 3D imaging with proprietary 'True-Map Navigation™,' which uses the live patient anatomy as a map for real-time instrument tracking. The system also incorporates AI technologies for intraoperative planning, guidance, and quality control.

nView operates in the highly competitive surgical navigation market, dominated by giants like Medtronic (StealthStation), Stryker (SpineMask, Q Guidance), and Zimmer Biomet (ROSA). Its key differentiation is the seamless integration of instant, low-dose 3D imaging with real-time navigation on the live anatomical map, a workflow advantage over systems that may rely on pre-operative scans or less precise registration. However, competitors have vast resources, broad product portfolios, and deep customer relationships.